Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandeep Tyagi

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Plos Neglected Tropical Diseases|August 14, 2018
Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcerPaul J Converse, Deepak V Almeida, Rokeya Tasneen, et al.
Antimicrobial Agents and Chemotherapy|February 20, 2024
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosisSi-Yang Li, Sandeep Tyagi, Heena Soni, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2026
BCG vaccination mitigates tau pathology and restores cognitive function in PS19 miceSomnath Shee, Meixiang Huang, Meghraj Singh Baghel, et al.
Nature Communications|August 24, 2024
Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimenNatasha Strydom, Jacqueline P Ernest, Marjorie Imperial, et al.
Plos One|May 3, 2018
A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosisStéphane Leung-Theung-Long, Charles-Antoine Coupet, Marie Gouanvic, et al.
Antimicrobial Agents and Chemotherapy|September 30, 2024
Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosisLourdes Encinas, Si-Yang Li, Joaquin Rullas-Trincado, et al.
Plos One|April 28, 2010
The impact of mouse passaging of Mycobacterium tuberculosis strains prior to virulence testing in the mouse and guinea pig aerosol modelsPaul J Converse, Kathleen D Eisenach, Sue A Theus, et al.
Nature Communications|January 18, 2025
The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosisAndreas Römpp, Axel Treu, Julia Kokesch-Himmelreich, et al.
Antimicrobial Agents and Chemotherapy|May 9, 2018
Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of TuberculosisNicole C Ammerman, Rosemary V Swanson, Elaine M Bautista, et al.
Science (New York, N.Y.)|June 6, 2015
Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycinsAngela Kling, Peer Lukat, Deepak V Almeida, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Plos Neglected Tropical Diseases|August 14, 2018
Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcerPaul J Converse, Deepak V Almeida, Rokeya Tasneen, et al.
Antimicrobial Agents and Chemotherapy|February 20, 2024
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosisSi-Yang Li, Sandeep Tyagi, Heena Soni, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2026
BCG vaccination mitigates tau pathology and restores cognitive function in PS19 miceSomnath Shee, Meixiang Huang, Meghraj Singh Baghel, et al.
Nature Communications|August 24, 2024
Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimenNatasha Strydom, Jacqueline P Ernest, Marjorie Imperial, et al.
Plos One|May 3, 2018
A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosisStéphane Leung-Theung-Long, Charles-Antoine Coupet, Marie Gouanvic, et al.
Antimicrobial Agents and Chemotherapy|September 30, 2024
Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosisLourdes Encinas, Si-Yang Li, Joaquin Rullas-Trincado, et al.
Plos One|April 28, 2010
The impact of mouse passaging of Mycobacterium tuberculosis strains prior to virulence testing in the mouse and guinea pig aerosol modelsPaul J Converse, Kathleen D Eisenach, Sue A Theus, et al.
Nature Communications|January 18, 2025
The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosisAndreas Römpp, Axel Treu, Julia Kokesch-Himmelreich, et al.
Antimicrobial Agents and Chemotherapy|May 9, 2018
Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of TuberculosisNicole C Ammerman, Rosemary V Swanson, Elaine M Bautista, et al.
Science (New York, N.Y.)|June 6, 2015
Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycinsAngela Kling, Peer Lukat, Deepak V Almeida, et al.
Pageof 8